Donna M Evon1, Carol E Golin2, Teodora Stoica3, Rachel E Jones3, Sarah J Willis4, Joseph Galanko3, Michael W Fried3. 1. Division of Gastroenterology and Hepatology, University of North Carolina, CB# 7584, 8010 Burnett-Womack, Chapel Hill, NC, 27599, USA. donna_evon@med.unc.edu. 2. Department of Medicine, Department of Health Behavior, University of North Carolina, Chapel Hill, NC, USA. 3. Division of Gastroenterology and Hepatology, University of North Carolina, CB# 7584, 8010 Burnett-Womack, Chapel Hill, NC, 27599, USA. 4. Department of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
Abstract
BACKGROUND AND OBJECTIVES: Multiple treatment options with direct-acting antivirals are now available for hepatitis C virus (HCV). Study aims were to understand (1) the informational topics patients want to have to make informed treatment decisions; (2) the importance patients place on each topic; and (3) the topics patients prioritize as most important. METHODS: We used a mixed-methods study of two samples recruited from an academic liver center. Participants were not currently on treatment. Sample I (n = 45) free listed all informational topics deemed important to decision making. Raw responses were coded into several broad and subcategories. Sample II (n = 38) rated the importance of the subcategories from Sample I and ranked their highest priorities on two surveys, one containing topics for which sufficient research existed to inform patients ('static'), and the other containing topics that would require additional research. RESULTS: The topics listed by Sample I fell into six broad categories with 17 total subcategories. The most oft-cited informational topics were harms of treatment (100%), treatment benefits (62%), and treatment regimen details (84%). Sample II rated 16 of 17 subcategories as "pretty important' or "extremely important". Sample II prioritized (1) viral cure, (2) long-term survival, and (3) side effects on the survey of topics requiring additional research, and (1) liver disease, (2) lifestyle changes, and (3) medication details on the second survey of the most important static topics patients needed. CONCLUSIONS: Patients weighed several informational topics to make an informed decision about HCV treatment. These findings lay the groundwork for future patient-centered outcomes research in HCV and patient-provider communication to enhance patients' informed decision making regarding direct-acting antiviral treatment options.
BACKGROUND AND OBJECTIVES: Multiple treatment options with direct-acting antivirals are now available for hepatitis C virus (HCV). Study aims were to understand (1) the informational topics patients want to have to make informed treatment decisions; (2) the importance patients place on each topic; and (3) the topics patients prioritize as most important. METHODS: We used a mixed-methods study of two samples recruited from an academic liver center. Participants were not currently on treatment. Sample I (n = 45) free listed all informational topics deemed important to decision making. Raw responses were coded into several broad and subcategories. Sample II (n = 38) rated the importance of the subcategories from Sample I and ranked their highest priorities on two surveys, one containing topics for which sufficient research existed to inform patients ('static'), and the other containing topics that would require additional research. RESULTS: The topics listed by Sample I fell into six broad categories with 17 total subcategories. The most oft-cited informational topics were harms of treatment (100%), treatment benefits (62%), and treatment regimen details (84%). Sample II rated 16 of 17 subcategories as "pretty important' or "extremely important". Sample II prioritized (1) viral cure, (2) long-term survival, and (3) side effects on the survey of topics requiring additional research, and (1) liver disease, (2) lifestyle changes, and (3) medication details on the second survey of the most important static topics patients needed. CONCLUSIONS:Patients weighed several informational topics to make an informed decision about HCV treatment. These findings lay the groundwork for future patient-centered outcomes research in HCV and patient-provider communication to enhance patients' informed decision making regarding direct-acting antiviral treatment options.
Authors: Glyn Elwyn; Annette O'Connor; Dawn Stacey; Robert Volk; Adrian Edwards; Angela Coulter; Richard Thomson; Alexandra Barratt; Michael Barry; Steven Bernstein; Phyllis Butow; Aileen Clarke; Vikki Entwistle; Deb Feldman-Stewart; Margaret Holmes-Rovner; Hilary Llewellyn-Thomas; Nora Moumjid; Al Mulley; Cornelia Ruland; Karen Sepucha; Alan Sykes; Tim Whelan Journal: BMJ Date: 2006-08-14
Authors: Annette M O'Connor; John E Wennberg; France Legare; Hilary A Llewellyn-Thomas; Benjamin W Moulton; Karen R Sepucha; Andrea G Sodano; Jaime S King Journal: Health Aff (Millwood) Date: 2007 May-Jun Impact factor: 6.301
Authors: Jessica L Zuchowski; Alison B Hamilton; Jeffrey M Pyne; Jack A Clark; Aanand D Naik; Donna L Smith; Fasiha Kanwal Journal: BMC Gastroenterol Date: 2015-10-01 Impact factor: 3.067
Authors: Donna M Evon; Carol E Golin; Paul Stewart; Michael W Fried; Shani Alston; Bryce Reeve; Anna S Lok; Richard K Sterling; Joseph K Lim; Nancy Reau; Souvik Sarkar; David R Nelson; K R Reddy; Adrian M Di Bisceglie Journal: Contemp Clin Trials Date: 2017-03-22 Impact factor: 2.226
Authors: T Joseph Mattingly; Julia F Slejko; Eleanor M Perfetto; Shyamasundaran Kottilil; C Daniel Mullins Journal: Patient Date: 2019-12 Impact factor: 3.883
Authors: Donna M Evon; Souvik Sarkar; Jipcy Amador; Anna S Lok; Richard K Sterling; Paul W Stewart; Bryce B Reeve; Marina Serper; Nancy Reau; K Rajender Reddy; Adrian M Di Bisceglie; David R Nelson; Carol E Golin; Joseph K Lim; Michael W Fried Journal: J Hepatol Date: 2019-05-13 Impact factor: 30.083
Authors: Scott Kixmiller; Anquenette P Sloan; Summer Wadsworth; Finton Brown; Lourdes Chaney; Larry Houston; Kim Thomas Journal: Res Involv Engagem Date: 2021-01-25